No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company is structured into two principal operating segments: CSL Behring and CSL Seqirus. CSL Behring focuses on plasma-derived therapies, encompassing both plasma products and recombinant treatments. This segment also conducts significant research into both plasma and non-plasma therapeutics and derives revenue from intellectual property licensing and royalties. In contrast, CSL Seqirus is dedicated to the manufacturing and worldwide distribution of non-plasma biotherapeutic products, alongside developing a range of influenza-related solutions. Founded in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.
www.csl.comNo one on the platform currently holds CSL.AX.
No tracked institution reports a position in CSL.AX as of their last filing.
No one on the platform has traded CSL.AX yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | 4.0% | 9.2% | ||||
| Profit Margin % | -16.4% | 11.8% | 16.8% | |||
| Free Cash Flow Margin % | 18.3% | 15.2% | 12.9% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $15.2B | -1.1% | $6.00 | $5.82–$6.36 | — | 13 |
| 2028 | $15.7B | +3.4% | $6.48 | $6.05–$6.85 | — | 14 |
| 2029 | $16.4B | +4.1% | $6.91 | $6.37–$7.49 | — | 10 |
| 2030 | $17.2B | +4.8% | $7.26 | $6.92–$7.51 | — | 8 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-17 | $3.28 | $3.15 | -4.0% |
| 2026-02-10 | $5.84 | $5.68 | -2.7% |
| 2025-08-18 | $4.04 | $3.62 | -10.4% |
| 2025-02-10 | $6.95 | $6.76 | -2.7% |
| 2024-08-12 | $2.70 | $2.74 | +1.5% |
| 2024-02-12 | $5.98 | $6.14 | +2.7% |
| 2023-08-14 | $6.25 | $6.42 | +2.7% |
| 2023-02-13 | $5.06 |
| $5.53 |
| +9.3% |
| $246259 |
| — |
| CUV.AXClinuvel Pharmaceuticals Limited | $8.36 | +0.60% | $421M | — |
| EZZ.AXEZZ Life Science Holdings Limited | $0.43 | -7.45% | $20M | — |
Source: Financial Modeling Prep · peers by sector/industry